UBS Group’s Guardion Health Sciences, Inc. Common Stock GHSI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-17,190
| Closed | -$95.2K | – | 10739 |
|
|
2024
Q3 | $95.2K | Buy |
17,190
+13,597
| +378% | +$138K | ﹤0.01% | 6410 |
|
|
2024
Q2 | $36.1K | Buy |
3,593
+2,421
| +207% | +$21.5K | ﹤0.01% | 6939 |
|
|
2024
Q1 | $10.6K | Buy |
+1,172
| New | +$8.65K | ﹤0.01% | 7219 |
|
|
2023
Q3 | – | Sell |
-43
| Closed | -$335 | – | 10125 |
|
|
2023
Q2 | $335 | Buy |
+43
| New | +$270 | ﹤0.01% | 8299 |
|
|
2023
Q1 | – | Sell |
-3,052
| Closed | -$22.9K | – | 10693 |
|
|
2022
Q4 | $22.9K | Hold |
3,052
| – | – | ﹤0.01% | 7509 |
|
|
2022
Q3 | $21K | Buy |
3,052
+1,494
| +96% | +$11.4K | ﹤0.01% | 7352 |
|
|
2022
Q2 | $11K | Buy |
1,558
+27
| +2% | +$236 | ﹤0.01% | 7867 |
|
|
2022
Q1 | $18K | Buy |
1,531
+1,105
| +259% | +$22.4K | ﹤0.01% | 7597 |
|
|
2021
Q4 | $14K | Buy |
426
+272
| +177% | +$14.6K | ﹤0.01% | 8366 |
|
|
2021
Q3 | $10K | Buy |
+154
| New | +$10.2K | ﹤0.01% | 8028 |
|
|
2021
Q2 | – | Sell |
-16
| Closed | -$2K | – | 9937 |
|
|
2021
Q1 | $2K | Buy |
+16
| New | +$3.23K | ﹤0.01% | 8662 |
|
|
2020
Q4 | – | Sell |
-412
| Closed | -$25K | – | 8860 |
|
|
2020
Q3 | $25K | Buy |
412
+100
| +32% | +$10.4K | ﹤0.01% | 6137 |
|
|
2020
Q2 | $41K | Buy |
312
+213
| +215% | +$29.7K | ﹤0.01% | 6045 |
|
|
2020
Q1 | $14K | Sell |
99
-209
| -68% | -$22.1K | ﹤0.01% | 6740 |
|
|
2019
Q4 | $20K | Buy |
308
+280
| +1,000% | +$26.7K | ﹤0.01% | 6886 |
|
|
2019
Q3 | $6K | Buy |
+28
| New | +$6.34K | ﹤0.01% | 7434 |
|
UBS Group's GHSI Position: Q4 2024 in Review
UBS Group sold out of Guardion Health Sciences, Inc. Common Stock (GHSI) in Q4 2024, closing a stake of 17,190 shares — an estimated $95.2K sold.
UBS Group first reported a position in GHSI in Q3 2019 and held it in 16 quarters. The position peaked at $95.2K in Q3 2024. 0 funds tracked by Wall St. Rank hold GHSI as of Q4 2024.
- UBS Group reported no remaining Guardion Health Sciences, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
- UBS Group sold 17,190 Guardion Health Sciences, Inc. Common Stock shares in Q4 2024, an estimated $95.2K.
- UBS Group first reported a position in Guardion Health Sciences, Inc. Common Stock in Q3 2019 and held it in 16 quarters.
- UBS Group's Guardion Health Sciences, Inc. Common Stock position peaked at $95.2K in Q3 2024.
- 0 funds tracked by Wall St. Rank held Guardion Health Sciences, Inc. Common Stock as of Q4 2024.
Based on UBS Group's 13F filing for Q4 2024, filed 14 Feb 2025.